CA2176825A1 - C5a receptor antagonists having substantially no agonist activity - Google Patents

C5a receptor antagonists having substantially no agonist activity

Info

Publication number
CA2176825A1
CA2176825A1 CA002176825A CA2176825A CA2176825A1 CA 2176825 A1 CA2176825 A1 CA 2176825A1 CA 002176825 A CA002176825 A CA 002176825A CA 2176825 A CA2176825 A CA 2176825A CA 2176825 A1 CA2176825 A1 CA 2176825A1
Authority
CA
Canada
Prior art keywords
analogue
human
antibody
seq
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002176825A
Other languages
English (en)
French (fr)
Inventor
Jan Van Oostrum
William C. Boyar
Nicholas G. Galakatos
Jane V. Peppard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2176825A1 publication Critical patent/CA2176825A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
CA002176825A 1993-12-06 1994-11-16 C5a receptor antagonists having substantially no agonist activity Abandoned CA2176825A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16259193A 1993-12-06 1993-12-06
US08/162,591 1993-12-06

Publications (1)

Publication Number Publication Date
CA2176825A1 true CA2176825A1 (en) 1995-06-15

Family

ID=22586301

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002176825A Abandoned CA2176825A1 (en) 1993-12-06 1994-11-16 C5a receptor antagonists having substantially no agonist activity

Country Status (15)

Country Link
EP (1) EP0733107A1 (de)
JP (1) JPH09506258A (de)
CN (1) CN1142854A (de)
AU (1) AU698919B2 (de)
BR (1) BR9408265A (de)
CA (1) CA2176825A1 (de)
FI (1) FI962319A (de)
HU (1) HUT75990A (de)
IL (1) IL111792A0 (de)
MX (1) MXPA99008669A (de)
NO (1) NO962348L (de)
NZ (1) NZ274917A (de)
TW (1) TW429262B (de)
WO (1) WO1995016033A1 (de)
ZA (1) ZA949647B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
AU6125096A (en) * 1995-06-05 1996-12-24 Novartis Ag C5a receptor antagonists having substantially no agonist activity and methods for preparation
WO1997022216A1 (en) * 1995-12-13 1997-06-19 Northern Telecom Limited Integrated cellular voice and digital packet data telecommunications systems and methods for their operation
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
TWI767415B (zh) * 2020-11-18 2022-06-11 中國醫藥大學 自動化血液分析系統及自動化血液分析方法
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305615A1 (de) * 1987-09-03 1989-03-08 Immunetech Pharmaceuticals, Inc. Peptidantagonisten für C5a-Anaphylotoxin
EP0245993B1 (de) * 1986-04-28 1993-05-26 Cetus Oncology Corporation Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
HUT75990A (en) 1997-05-28
JPH09506258A (ja) 1997-06-24
ZA949647B (en) 1995-06-06
AU8002594A (en) 1995-06-27
FI962319A0 (fi) 1996-06-03
NO962348D0 (no) 1996-06-05
WO1995016033A1 (en) 1995-06-15
MXPA99008669A (es) 2004-09-01
AU698919B2 (en) 1998-11-12
HU9601538D0 (en) 1996-07-29
CN1142854A (zh) 1997-02-12
IL111792A0 (en) 1995-01-24
EP0733107A1 (de) 1996-09-25
TW429262B (en) 2001-04-11
NO962348L (no) 1996-08-05
NZ274917A (en) 1998-03-25
FI962319A (fi) 1996-06-03
BR9408265A (pt) 1996-12-10

Similar Documents

Publication Publication Date Title
CA1339210C (en) Recombinant techniques for production of novel natriuretic and vasodilator peptides
Esch et al. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF.
Takahashi et al. Cloning and sequencing of cDNA of Sarcophaga peregrina humoral lectin induced on injury of the body wall.
JP2774769B2 (ja) アドレノメデュリン
US4980279A (en) Cellular fibronectin: polypeptides, anti-polypeptide antibodies and assay methods
JPH06506596A (ja) インターロイキン−８受容体及び関連分子及び方法
JP2002511262A (ja) Ｎｇｆに関する治療薬
US5807824A (en) C5A receptor antagonists having substantially no agonist activity
US4716148A (en) Prothymosin alpha
US20030170620A1 (en) Peptides and polypeptides derived from the submaxillary gland of the rat corresponding polyclonal and monoclonal antibodies corresponding hybridomas and uses of these products for diagnosis for detection or therapeutic purposes
US6573244B1 (en) Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
US20040101509A1 (en) Chemokine mutants in the treatment of multiple sclerosis
CA2176825A1 (en) C5a receptor antagonists having substantially no agonist activity
JPH11503030A (ja) 哺乳動物ｃｘ３ｃケモカイン遺伝子
JP3330953B2 (ja) 医薬製剤の製造における活性化プロテインｃの使用
US5476839A (en) Basophil granule proteins
EP0832223A1 (de) Antagonisten von c 5a-rezeptoren ohne agonistische wirkung und verfahren zu deren herstellung
WO1996021006A1 (en) Novel phosphoprotein secreted in the extracellular matrices of mammalian organs and methods for use thereof
US5837499A (en) DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
US6537794B1 (en) Chemokine
CA2046925A1 (en) Pregnancy specific proteins applications
US6756211B1 (en) Neutropohil inhibitors
JP4290564B2 (ja) Ｃ５ａアナフィラトキシンの突然変異タンパク質、このような突然変異タンパク質をコードする核酸分子ならびにＣ５ａアナフィラトキシンの突然変異タンパク質の医薬的使用
US6489451B1 (en) Antithrombosis enzyme from the snake venom of agkistrodon acutus
EP0651800B1 (de) Proteine aus granulabasophilen zellen

Legal Events

Date Code Title Description
FZDE Discontinued